Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $115

Benzinga Newsdesk www.benzinga.com Positive 83.7%

Neg 0% Neu 0% Pos 83.7%

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $90 to $115.